Introduction: Infectious diseases are one of the most frequent reasons for hospital admission for children and antimicrobials are commonly used to treat them. There is higher prevalence of irrational prescriptions of antimicrobials in such population. This study was conducted to survey the pattern of antimicrobial prescription in Paediatric inpatient. Material and Methods: This was retrospective, descriptive, observational study. The data was collected from prescription records. The paediatric population included in the study was categorised into three age groups. A total of 87 prescriptions were studied and the information was recorded in performa. Data were recorded in MS Excel and Graph Pad Prism version 6 was used for analysis. Results: The number of male child was outnumbered by female child. The average age of the patient on antimicrobial prescription was 5.34 ± 2.18 years. The mean duration of hospital stay was 6.17 ± 2.01 days. The common indications for antimicrobial prescriptions were upper respiratory tract infections, diarrhoeal illness, urinary tract infections, enteric fever, etc. The antimicrobials prescription rate was 1.33. Oral route was found to be commonly used than parenteral route. The generic prescription rate was 33.6%. The most common drug prescribed was ceftriaxone followed by amoxicillin + clavulanic acid, ciprofloxacin, metronidazole and amikacin. The 62.5% of antimicrobials were prescribed from National Essential List of Medicines. Conclusion: This study highlights the prescription pattern of antimicrobial agents in hospitalised Paediatric population in a tertiary care hospital.

Introduction: The ChAdOx 1 n Cov-19 vaccine, called Covishield, was rolled out in Nepal targeting health care professionals. The study was conducted to assess the pattern of self-reported adverse events following immunization and to compare AEFI on the basis of previous COVID status. Methods: A cross sectional study of four months duration was conducted in Shree Birendra Hospital, a tertiary care hospital, in Kathmandu, Nepal.  AEFI associated with first and second dose of Covishield were assessed for a period of seven days from the day of vaccination in health care professionals and comparison was done based on COVID status. Results: A total of 100 vaccine recipients were included in the study, out of which 83% showed AEFI. The most commonly reported AEFI after first dose were headache (56%), injection site tenderness (42%), myalgia (29%), fatigue (24%), dizziness (20%), pyrexia (19%), malaise (17%), nausea (10%), chills (8%), vomiting (2%) and arthralgia (1%) while among the AEFI after second dose were injection site tenderness (36%), headache (15%), myalgia (12%), fatigue (11%), nausea (9%), malaise (8%), pyrexia (8%), chills (5%), rashes (3%), drowsiness (3%), arthralgia (1%) and dizziness (1%). Previously infected participants were found to be prone to develop systemic adverse effects. The most of the adverse effects were subsided within four days and commonly used medication was paracetamol to relieve the symptoms.   Conclusions: AEFI following the first and second dose of vaccine were mild. Systemic adverse effects were more frequent in those with the history of COVID-19 infection.